Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1970 3
1973 2
1974 1
1976 2
1977 1
1978 2
1984 1
1985 2
1989 3
1990 4
1991 2
1992 1
1995 2
1996 2
1997 6
1998 1
2000 4
2001 3
2002 5
2003 2
2004 2
2005 4
2006 3
2007 8
2008 8
2009 11
2010 10
2011 15
2012 13
2013 7
2014 20
2015 15
2016 12
2017 21
2018 25
2019 28
2020 46
2021 32
2022 35
2023 35
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Results by year

Filters applied: . Clear all
Page 1
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. Henter JI, et al. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039. Pediatr Blood Cancer. 2007. PMID: 16937360
HLH-2004 chemo-immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids. Subsequent hematopoietic stem cell transplantation (HSCT) is recommended for patients with familial …
HLH-2004 chemo-immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy …
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.
Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL. Abla O, et al. Blood. 2018 Jun 28;131(26):2877-2890. doi: 10.1182/blood-2018-03-839753. Epub 2018 May 2. Blood. 2018. PMID: 29720485 Free PMC article. Review.
Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. ...Although in most cases RDD can be observed or treated with local therapies, some …
Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation …
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI. La Rosée P, et al. Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16. Blood. 2019. PMID: 30992265 Free article.
Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults.
Hines MR, von Bahr Greenwood T, Beutel G, Beutel K, Hays JA, Horne A, Janka G, Jordan MB, van Laar JAM, Lachmann G, Lehmberg K, Machowicz R, Miettunen P, La Rosée P, Shakoory B, Zinter MS, Henter JI. Hines MR, et al. Crit Care Med. 2022 May 1;50(5):860-872. doi: 10.1097/CCM.0000000000005361. Epub 2021 Oct 5. Crit Care Med. 2022. PMID: 34605776
OBJECTIVE: Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome that often requires critical care support and remains difficult to diagnose. These guidelines are meant to aid in the early recognition, diagnosis, supportive care, and treatment of patien …
OBJECTIVE: Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome that often requires critical care support and remains d …
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. Goyal G, et al. Blood. 2020 May 28;135(22):1929-1945. doi: 10.1182/blood.2019003507. Blood. 2020. PMID: 32187362 Free article. Review.
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. ...With the recent molecular discoveries and the approval of the first targe …
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of …
Inpatient recognition and management of HLH.
Zoref-Lorenz A, Ellis M, Jordan MB. Zoref-Lorenz A, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):259-266. doi: 10.1182/hematology.2023000509. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066887 Review.
The main clinical challenges are recognizing HLH, determining whether the immune response is aberrant or appropriate, and deciding upon therapy. Patients may present with fever, central nervous system symptoms, cytopenias, or elevated liver enzymes. ...Once HLH is diagnose …
The main clinical challenges are recognizing HLH, determining whether the immune response is aberrant or appropriate, and deciding upon t …
Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.
Henderson LA, Cron RQ. Henderson LA, et al. Paediatr Drugs. 2020 Feb;22(1):29-44. doi: 10.1007/s40272-019-00367-1. Paediatr Drugs. 2020. PMID: 31732958 Free PMC article. Review.
With a better understanding of the pathophysiology of MAS and the advent of novel therapeutics, a broad immunosuppressive approach to treatment is giving way to targeted anti-cytokine therapies. ...Increased early recognition of MAS among pediatric inflammatory diso …
With a better understanding of the pathophysiology of MAS and the advent of novel therapeutics, a broad immunosuppressive approach to …
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C, Nichols KE, Albeituni S. Keenan C, et al. Front Immunol. 2021 Feb 16;12:614704. doi: 10.3389/fimmu.2021.614704. eCollection 2021. Front Immunol. 2021. PMID: 33664745 Free PMC article. Review.
To improve upon these results, studies have focused on the use of novel cytokine-directed therapies to dampen inflammation in HLH. Among the agents being tested is ruxolitinib, a potent inhibitor of the Janus Kinase (JAK) and Signal Transducer and Activation of Transcripti …
To improve upon these results, studies have focused on the use of novel cytokine-directed therapies to dampen inflammation in HLH. Am …
Macrophage Activation Syndrome in Children: Diagnosis and Management.
Bagri NK, Gupta L, Sen ES, Ramanan AV. Bagri NK, et al. Indian Pediatr. 2021 Dec 15;58(12):1155-1161. doi: 10.1007/s13312-021-2399-8. Epub 2021 Mar 26. Indian Pediatr. 2021. PMID: 33772536 Free PMC article. Review.
If unchecked, it may lead to multiorgan failure and mortality. Early diagnosis and timely initiation of specific therapy is pivotal for a successful outcome. This review outlines the key clinical and laboratory features and management of macrophage activation syndrome....
If unchecked, it may lead to multiorgan failure and mortality. Early diagnosis and timely initiation of specific therapy is pivotal f …
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, Hines M, Eckstein O, Ladisch S, Nichols KE, Rodriguez-Galindo C, Wistinghausen B, McClain KL. Jordan MB, et al. Pediatr Blood Cancer. 2019 Nov;66(11):e27929. doi: 10.1002/pbc.27929. Epub 2019 Jul 24. Pediatr Blood Cancer. 2019. PMID: 31339233 Free PMC article. Review.
360 results